首页 > 最新文献

Investigative and Clinical Urology最新文献

英文 中文
Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder. Mirabek®治疗成人膀胱过动症的疗效和安全性的多中心、前瞻性、非介入性观察性研究
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240278
Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham

Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek®) in adults diagnosed with OAB through a multicenter, prospective, non-interventional observational study.

Materials and methods: Adult patients with OAB prescribed Mirabek® SR Tab. 50 mg for the first time were recruited from hospitals between September 2021 and September 2022. Participants underwent baseline registration followed by two follow-ups at 4- and 8-week intervals. Data on demographics, medical history, OAB symptoms, vital signs, medication administration, and adverse events were collected.

Results: Among 1,714 patients, Mirabek® SR Tab. 50 mg effectively improved OAB symptoms over an 8-week treatment period, with significant differences in symptom improvement between baseline and both 4- and 8-week time points as well as between 4 weeks and 8 weeks. The incidence rate of adverse events was 0.70%; most cases were mild with no severe reactions.

Conclusions: This study demonstrated that Mirabek®, a generic drug of betmiga, is an effective and safe treatment option for adults with OAB. Furthermore, the introduction of generic drug reduced the costs of prescription drugs and expanded the opportunity for many patients to access mirabegron.

目的:Mirabegron是一种一流的β -3激动剂,是治疗膀胱过动症(OAB)的主要药物。本研究的目的是通过一项多中心、前瞻性、非介入性观察性研究,探讨仿制药米拉贝龙(Mirabek®)对成年OAB患者的疗效和安全性。材料与方法:于2021年9月至2022年9月从医院招募首次使用Mirabek®SR Tab. 50 mg的成年OAB患者。参与者先进行基线登记,然后在4周和8周的间隔进行两次随访。收集了人口统计学、病史、OAB症状、生命体征、药物管理和不良事件的数据。结果:在1714名患者中,Mirabek®SR Tab. 50 mg在8周的治疗期内有效改善了OAB症状,在基线、4周和8周时间点以及4周和8周时间点之间的症状改善有显著差异。不良事件发生率为0.70%;大多数病例轻微,无严重反应。结论:本研究表明,betmiga的仿制药Mirabek®是一种有效且安全的成人OAB治疗选择。此外,仿制药的引入降低了处方药的成本,并扩大了许多患者获得mirabegron的机会。
{"title":"Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek<sup>®</sup> in adult patients with overactive bladder.","authors":"Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham","doi":"10.4111/icu.20240278","DOIUrl":"10.4111/icu.20240278","url":null,"abstract":"<p><strong>Purpose: </strong>Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek<sup>®</sup>) in adults diagnosed with OAB through a multicenter, prospective, non-interventional observational study.</p><p><strong>Materials and methods: </strong>Adult patients with OAB prescribed Mirabek<sup>®</sup> SR Tab. 50 mg for the first time were recruited from hospitals between September 2021 and September 2022. Participants underwent baseline registration followed by two follow-ups at 4- and 8-week intervals. Data on demographics, medical history, OAB symptoms, vital signs, medication administration, and adverse events were collected.</p><p><strong>Results: </strong>Among 1,714 patients, Mirabek<sup>®</sup> SR Tab. 50 mg effectively improved OAB symptoms over an 8-week treatment period, with significant differences in symptom improvement between baseline and both 4- and 8-week time points as well as between 4 weeks and 8 weeks. The incidence rate of adverse events was 0.70%; most cases were mild with no severe reactions.</p><p><strong>Conclusions: </strong>This study demonstrated that Mirabek<sup>®</sup>, a generic drug of betmiga, is an effective and safe treatment option for adults with OAB. Furthermore, the introduction of generic drug reduced the costs of prescription drugs and expanded the opportunity for many patients to access mirabegron.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"27-35"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ablation of IGFBP5 expression alleviates neurogenic erectile dysfunction by inducing neurovascular regeneration. 消融IGFBP5表达可通过诱导神经血管再生减轻神经源性勃起功能障碍。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240325
Jiyeon Ock, Guo Nan Yin, Fang-Yuan Liu, Yan Huang, Fitri Rahma Fridayana, Minh Nhat Vo, Ji-Kan Ryu

Purpose: To investigate the therapeutic potential of eliminating insulin-like growth factor-binding protein 5 (IGFBP5) expression in improving erectile function in mice with cavernous nerve injury (CNI)-induced erectile dysfunction (ED).

Materials and methods: Eight-week-old male C57BL/6 mice were divided into four groups: a sham-operated group and three CNI-induced ED groups. The CNI-induced ED groups were treated with intracavernous injections 3 days before the CNI procedure. These injections included phosphate-buffered saline, scrambled control short hairpin RNA (shRNA), or shRNA targeting mouse IGFBP5 lentiviral particles. One week after CNI, erectile function was evaluated and the penile tissue was then harvested for histological examination and western blot analysis. Additionally, the major pelvic ganglia (MPG) and dorsal root ganglia (DRG) were cultured for ex vivo neurite outgrowth assays.

Results: Following CNI, IGFBP5 expression in the cavernous tissues significantly increased, reaching its peak at day 7. First, ablation of IGFBP5 expression promotes neurite sprouting in MPG and DRG when exposed to lipopolysaccharide. Second, ablating IGFBP5 expression in CNI-induced ED mice improved erectile function, likely owing to increased neurovascular contents, including endothelial cells, pericytes, and neuronal processes. Third, ablating IGFBP5 expression in CNI-induced ED mice promoted neurovascular regeneration by increasing cell proliferation, reducing apoptosis, and decreasing Reactive oxygen species production. Finally, western blot analysis demonstrated that IGFBP5 ablation attenuated the JNK/c-Jun signaling pathway, activated the PI3K/AKT signaling pathway, and increased vascular endothelial growth factor and neurotrophic factor expression.

Conclusions: Ablating IGFBP5 expression enhanced neurovascular regeneration and ultimately improved erectile function in CNI-induced ED mice.

目的:探讨消除胰岛素样生长因子结合蛋白5 (IGFBP5)表达对改善海绵体神经损伤(CNI)所致勃起功能障碍(ED)小鼠勃起功能的治疗作用。材料与方法:将8周龄雄性C57BL/6小鼠分为4组:假手术组和cni诱导ED组。CNI诱导ED组在CNI手术前3天进行海绵内注射。这些注射包括磷酸盐缓冲盐水,打乱控制的短发夹RNA (shRNA),或靶向小鼠IGFBP5慢病毒颗粒的shRNA。CNI后一周,评估勃起功能,然后收集阴茎组织进行组织学检查和western blot分析。此外,培养大盆腔神经节(MPG)和背根神经节(DRG)进行体外神经突起生长试验。结果:CNI后,海绵体组织中IGFBP5表达显著升高,在第7天达到峰值。首先,当暴露于脂多糖时,IGFBP5表达的消融促进MPG和DRG中的神经突发芽。其次,在cni诱导的ED小鼠中,去除IGFBP5的表达可以改善勃起功能,这可能是由于增加了神经血管内容物,包括内皮细胞、周细胞和神经元突。第三,在cni诱导的ED小鼠中,去除IGFBP5的表达可以通过增加细胞增殖、减少细胞凋亡和减少活性氧的产生来促进神经血管再生。最后,western blot分析表明,IGFBP5消融可减弱JNK/c-Jun信号通路,激活PI3K/AKT信号通路,增加血管内皮生长因子和神经营养因子的表达。结论:切除IGFBP5表达可促进神经血管再生,最终改善cni诱导的ED小鼠勃起功能。
{"title":"Ablation of IGFBP5 expression alleviates neurogenic erectile dysfunction by inducing neurovascular regeneration.","authors":"Jiyeon Ock, Guo Nan Yin, Fang-Yuan Liu, Yan Huang, Fitri Rahma Fridayana, Minh Nhat Vo, Ji-Kan Ryu","doi":"10.4111/icu.20240325","DOIUrl":"10.4111/icu.20240325","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the therapeutic potential of eliminating insulin-like growth factor-binding protein 5 (IGFBP5) expression in improving erectile function in mice with cavernous nerve injury (CNI)-induced erectile dysfunction (ED).</p><p><strong>Materials and methods: </strong>Eight-week-old male C57BL/6 mice were divided into four groups: a sham-operated group and three CNI-induced ED groups. The CNI-induced ED groups were treated with intracavernous injections 3 days before the CNI procedure. These injections included phosphate-buffered saline, scrambled control short hairpin RNA (shRNA), or shRNA targeting mouse IGFBP5 lentiviral particles. One week after CNI, erectile function was evaluated and the penile tissue was then harvested for histological examination and western blot analysis. Additionally, the major pelvic ganglia (MPG) and dorsal root ganglia (DRG) were cultured for <i>ex vivo</i> neurite outgrowth assays.</p><p><strong>Results: </strong>Following CNI, IGFBP5 expression in the cavernous tissues significantly increased, reaching its peak at day 7. First, ablation of IGFBP5 expression promotes neurite sprouting in MPG and DRG when exposed to lipopolysaccharide. Second, ablating IGFBP5 expression in CNI-induced ED mice improved erectile function, likely owing to increased neurovascular contents, including endothelial cells, pericytes, and neuronal processes. Third, ablating IGFBP5 expression in CNI-induced ED mice promoted neurovascular regeneration by increasing cell proliferation, reducing apoptosis, and decreasing Reactive oxygen species production. Finally, western blot analysis demonstrated that IGFBP5 ablation attenuated the JNK/c-Jun signaling pathway, activated the PI3K/AKT signaling pathway, and increased vascular endothelial growth factor and neurotrophic factor expression.</p><p><strong>Conclusions: </strong>Ablating IGFBP5 expression enhanced neurovascular regeneration and ultimately improved erectile function in CNI-induced ED mice.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"74-86"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of a supplement associating Lactobacillus strains and proanthocyanidin-rich plant extracts against recurrent uncomplicated, urinary tract infections: A prospective, controlled study. 乳杆菌菌株和富含原花青素的植物提取物对复发性无并发症尿路感染的作用:一项前瞻性对照研究。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240092
Samira Ait Abdellah, Anne Leblanc, Quentin Dauchet, Claude Blondeau, Jean Marc Bohbot

Purpose: Recurrent cystitis, particularly common in women, substantially diminishes patient quality of life and represents a major clinical practice and public health burden. Increasing development of resistance to antibiotics has encouraged the search for alternative treatments. The benefits of a food supplement associating two Lactobacillus strains with proanthocyanidin A-rich cranberry and cinnamon extracts were evaluated in 80 women with a history of cystitis recurrence.

Materials and methods: Post-inclusion recurrence frequency was compared between women taking the investigated supplement daily for 6 months and non-supplemented women, based on patient-completed Acute Cystitis Symptom Score (ACSS) questionnaires.

Results: Two-thirds (64.9%) of supplemented women experienced no further episodes of cystitis during the first 6 months of the study compared to only one-third (31.6%) of non-supplemented women (p=0.004), the difference between the two groups being significant from 3 months onward. ACSS scores revealed significantly fewer and less severe urinary symptoms in supplemented women, as well as a significantly reduced impact of these symptoms on quality of life (p<0.0001).

Conclusions: The results shown by extensive data on women suffering from recurrent cystitis, collected over 8 months, indicate that taking the tested supplement daily for 6 months can provide significant benefits in terms of recurrence frequency, symptoms, and quality of life. The study is registered on the ClinicalTrials.gov site under the identifier NCT04987164.

目的:复发性膀胱炎,特别是在妇女中常见,大大降低了患者的生活质量,是一个主要的临床实践和公共卫生负担。抗生素耐药性的增加促使人们寻找替代治疗方法。在80名有膀胱炎复发史的妇女中,对两种乳杆菌菌株与富含原花青素a的蔓越莓和肉桂提取物的食物补充剂的益处进行了评估。材料和方法:根据患者填写的急性膀胱炎症状评分(ACSS)问卷,比较每日服用所研究补充剂的妇女和未服用补充剂的妇女在6个月内的纳入后复发率。结果:三分之二(64.9%)补充了维生素d的女性在研究的前6个月没有再发生膀胱炎,而未补充维生素d的女性只有三分之一(31.6%)(p=0.004),两组之间的差异在3个月后显著。ACSS评分显示,服用补充剂的女性的泌尿系统症状明显减少,严重程度也明显降低,这些症状对生活质量的影响也明显降低(结论:收集了8个月以上的复发性膀胱炎女性的大量数据,结果表明,连续6个月每天服用试验补充剂,在复发频率、症状和生活质量方面都有显著的好处。该研究已在ClinicalTrials.gov网站注册,标识符为NCT04987164。
{"title":"Effects of a supplement associating <i>Lactobacillus</i> strains and proanthocyanidin-rich plant extracts against recurrent uncomplicated, urinary tract infections: A prospective, controlled study.","authors":"Samira Ait Abdellah, Anne Leblanc, Quentin Dauchet, Claude Blondeau, Jean Marc Bohbot","doi":"10.4111/icu.20240092","DOIUrl":"10.4111/icu.20240092","url":null,"abstract":"<p><strong>Purpose: </strong>Recurrent cystitis, particularly common in women, substantially diminishes patient quality of life and represents a major clinical practice and public health burden. Increasing development of resistance to antibiotics has encouraged the search for alternative treatments. The benefits of a food supplement associating two <i>Lactobacillus</i> strains with proanthocyanidin A-rich cranberry and cinnamon extracts were evaluated in 80 women with a history of cystitis recurrence.</p><p><strong>Materials and methods: </strong>Post-inclusion recurrence frequency was compared between women taking the investigated supplement daily for 6 months and non-supplemented women, based on patient-completed Acute Cystitis Symptom Score (ACSS) questionnaires.</p><p><strong>Results: </strong>Two-thirds (64.9%) of supplemented women experienced no further episodes of cystitis during the first 6 months of the study compared to only one-third (31.6%) of non-supplemented women (p=0.004), the difference between the two groups being significant from 3 months onward. ACSS scores revealed significantly fewer and less severe urinary symptoms in supplemented women, as well as a significantly reduced impact of these symptoms on quality of life (p<0.0001).</p><p><strong>Conclusions: </strong>The results shown by extensive data on women suffering from recurrent cystitis, collected over 8 months, indicate that taking the tested supplement daily for 6 months can provide significant benefits in terms of recurrence frequency, symptoms, and quality of life. The study is registered on the ClinicalTrials.gov site under the identifier NCT04987164.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"36-46"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment.
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240263
Jeong Min Lee, Won Hyeok Lee, Seung Hyeon Cho, Jeong Woo Park, Hyuk Nam Kwon, Ji Hye Kim, Sang Hun Lee, Ji Hyung Yoon, Sungchan Park, Seong Cheol Kim

Purpose: Developmentally regulated GTP-binding protein 2 (DRG2) regulates microtubule dynamics and G2/M arrest during docetaxel treatment. Poly ADP-ribose polymerase (PARP) acts as an important repair system for DNA damage caused by docetaxel treatment. This study investigated whether DRG2 expression affects response to PARP inhibitors (olaparib) using prostate cancer cell lines PC3, DU145, LNCaP-FGC, and LNCaP-LN3.

Materials and methods: The cell viability and DRG2 expression levels were assessed using colorimetric-based cell viability assay and western blot. Cells were transfected with DRG2 siRNA, and pcDNA6/V5-DRG2 was used to overexpress DRG2. Flow cytometry was applied for cell cycle assay and apoptosis analysis using the Annexing V cell death assay.

Results: The expression of DRG2 was highest in LNCaP-LN3 and lowest in DU145 cells. Expressions of p53 in PC3, DU145, and the two LNCaP cell lines were null-type, high-expression, and medium-expression, respectively. In PC3 (DRG2 high, p53 null) cells, docetaxel increased G2/M arrest without apoptosis; however, subsequent treatment with olaparib promoted apoptosis. In DU145 and LNCaP-FGC (DRG2 low), docetaxel increased sub-G1 but not G2/M arrest and induced apoptosis, whereas olaparib had no additional effect. In LNCaP-LN3 (DRG2 high, p53 wild-type), docetaxel increased sub-G1 and G2/M arrest, furthermore olaparib enhanced cell death. Docetaxel and olaparib combination treatment had a slight effect on DRG2 knockdown PC3, but increased apoptosis in DRG2-overexpressed DU145 cells.

Conclusions: DRG2 and p53 expressions play an important role in prostate cancer cell lines treated with docetaxel, and DRG2 levels can predict the response to PARP inhibitors.

{"title":"DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment.","authors":"Jeong Min Lee, Won Hyeok Lee, Seung Hyeon Cho, Jeong Woo Park, Hyuk Nam Kwon, Ji Hye Kim, Sang Hun Lee, Ji Hyung Yoon, Sungchan Park, Seong Cheol Kim","doi":"10.4111/icu.20240263","DOIUrl":"https://doi.org/10.4111/icu.20240263","url":null,"abstract":"<p><strong>Purpose: </strong>Developmentally regulated GTP-binding protein 2 (DRG2) regulates microtubule dynamics and G2/M arrest during docetaxel treatment. Poly ADP-ribose polymerase (PARP) acts as an important repair system for DNA damage caused by docetaxel treatment. This study investigated whether DRG2 expression affects response to PARP inhibitors (olaparib) using prostate cancer cell lines PC3, DU145, LNCaP-FGC, and LNCaP-LN3.</p><p><strong>Materials and methods: </strong>The cell viability and DRG2 expression levels were assessed using colorimetric-based cell viability assay and western blot. Cells were transfected with DRG2 siRNA, and pcDNA6/V5-DRG2 was used to overexpress DRG2. Flow cytometry was applied for cell cycle assay and apoptosis analysis using the Annexing V cell death assay.</p><p><strong>Results: </strong>The expression of DRG2 was highest in LNCaP-LN3 and lowest in DU145 cells. Expressions of p53 in PC3, DU145, and the two LNCaP cell lines were null-type, high-expression, and medium-expression, respectively. In PC3 (DRG2 high, p53 null) cells, docetaxel increased G2/M arrest without apoptosis; however, subsequent treatment with olaparib promoted apoptosis. In DU145 and LNCaP-FGC (DRG2 low), docetaxel increased sub-G1 but not G2/M arrest and induced apoptosis, whereas olaparib had no additional effect. In LNCaP-LN3 (DRG2 high, p53 wild-type), docetaxel increased sub-G1 and G2/M arrest, furthermore olaparib enhanced cell death. Docetaxel and olaparib combination treatment had a slight effect on DRG2 knockdown PC3, but increased apoptosis in DRG2-overexpressed DU145 cells.</p><p><strong>Conclusions: </strong>DRG2 and p53 expressions play an important role in prostate cancer cell lines treated with docetaxel, and DRG2 levels can predict the response to PARP inhibitors.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"56-66"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model. 沙棘对盐酸致膀胱炎大鼠模型的抗炎作用。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240196
Hyun Suk Yoon, Juyeon Yu, Shinhoon Kang, Hana Yoon

Purpose: Although the mechanism underlying interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, oxidative stress is suggested to be implicated in IC/BPS development. Sea buckthorn (SB; Hippophae rhamnoides L.) contains several compounds with antioxidant properties. In addition, intravesical application of hydrochloric acid (HCl) in rats induces histological changes similar to those observed in humans with IC. Therefore, the aim of this study was to evaluate the anti-inflammatory effects of SB in an HCl-induced rat cystitis model.

Materials and methods: Twenty 8-week-old female Sprague-Dawley rats were instilled with HCl in their bladders to create an IC/BPS model. The model rats were divided into three groups and orally administrated distilled water (control, n=4), concentrated SB (n=8), or pentosan polysulfate (PPS, n=8) daily. Pathologic inflammation grade (H&E staining), number of mast cells per square millimeter (toluidine blue staining), fibrotic changes (Masson's trichrome staining), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling staining) of bladder tissue samples were compared among the groups.

Results: Compared to the control group, the SB and PPS groups showed reduced edema (5.25±0.96 vs. 2.25±0.46 vs. 2.50±0.54, p=0.004, p=0.005, respectively), number of mast cells (12.5±3.6 vs. 6.8±1.9 vs. 6.6±1.8, p=0.010, p=0.002, respectively), ratio of fibrotic submucosal tissue (63.9%±7.0% vs. 43.6%±9.9% vs. 40.5%±5.2%, p<0.001, p<0.001, respectively), and ratio of apoptotic nucleus (40.7%±11.7% vs. 7.7%±6.5% vs. 5.1%±4.9%, p<0.001, p<0.001, respectively).

Conclusions: SB exhibited anti-inflammatory effects comparable to those of PPS in the HCl-induced chemical cystitis model.

目的:虽然间质性膀胱炎/膀胱痛综合征(IC/BPS)的机制尚不清楚,但氧化应激提示与IC/BPS的发展有关。沙棘;沙棘(Hippophae rhamnoides L.)含有几种具有抗氧化特性的化合物。此外,大鼠膀胱内应用盐酸(HCl)可诱导与IC患者相似的组织学变化。因此,本研究的目的是在盐酸诱导的大鼠膀胱炎模型中评估SB的抗炎作用。材料与方法:将20只8周龄雌性sd大鼠膀胱灌注HCl,建立IC/BPS模型。将模型大鼠分为3组,每天口服蒸馏水(对照组,n=4)、浓缩SB (n=8)、聚硫酸戊聚糖(PPS, n=8)。比较各组膀胱组织病理炎症分级(H&E染色)、每平方毫米肥大细胞数(甲苯胺蓝染色)、纤维化改变(马松三色染色)、凋亡(末端脱氧核苷酸转移酶dUTP nick末端标记染色)。结果:与对照组比较,SB组和PPS组水肿减少(5.25±0.96比2.25±0.46比2.50±0.54,p=0.004, p=0.005),肥大细胞数量减少(12.5±3.6比6.8±1.9比6.6±1.8,p=0.010, p=0.002),粘膜下组织纤维化比例减少(63.9%±7.0%比43.6%±9.9%比40.5%±5.2%),结论:SB对盐酸致化学性膀胱炎模型的抗炎作用与PPS相当。
{"title":"Anti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model.","authors":"Hyun Suk Yoon, Juyeon Yu, Shinhoon Kang, Hana Yoon","doi":"10.4111/icu.20240196","DOIUrl":"10.4111/icu.20240196","url":null,"abstract":"<p><strong>Purpose: </strong>Although the mechanism underlying interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, oxidative stress is suggested to be implicated in IC/BPS development. Sea buckthorn (SB; <i>Hippophae rhamnoides</i> L.) contains several compounds with antioxidant properties. In addition, intravesical application of hydrochloric acid (HCl) in rats induces histological changes similar to those observed in humans with IC. Therefore, the aim of this study was to evaluate the anti-inflammatory effects of SB in an HCl-induced rat cystitis model.</p><p><strong>Materials and methods: </strong>Twenty 8-week-old female Sprague-Dawley rats were instilled with HCl in their bladders to create an IC/BPS model. The model rats were divided into three groups and orally administrated distilled water (control, n=4), concentrated SB (n=8), or pentosan polysulfate (PPS, n=8) daily. Pathologic inflammation grade (H&E staining), number of mast cells per square millimeter (toluidine blue staining), fibrotic changes (Masson's trichrome staining), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling staining) of bladder tissue samples were compared among the groups.</p><p><strong>Results: </strong>Compared to the control group, the SB and PPS groups showed reduced edema (5.25±0.96 vs. 2.25±0.46 vs. 2.50±0.54, p=0.004, p=0.005, respectively), number of mast cells (12.5±3.6 vs. 6.8±1.9 vs. 6.6±1.8, p=0.010, p=0.002, respectively), ratio of fibrotic submucosal tissue (63.9%±7.0% vs. 43.6%±9.9% vs. 40.5%±5.2%, p<0.001, p<0.001, respectively), and ratio of apoptotic nucleus (40.7%±11.7% vs. 7.7%±6.5% vs. 5.1%±4.9%, p<0.001, p<0.001, respectively).</p><p><strong>Conclusions: </strong>SB exhibited anti-inflammatory effects comparable to those of PPS in the HCl-induced chemical cystitis model.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"67-73"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multicenter micro-costing analysis of flexible cystoscopic procedures in Korea. 韩国灵活膀胱镜手术的多中心微观成本分析。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240289
Uiemo Je, Woong Kyu Han, Hee-Kyo Jeong, Hankil Lee, Kwang Suk Lee, Sung Ku Kang, Byeong-Ju Kwon, Sung-Uk Kuh

Purpose: This study aims to develop and implement an economic evaluation using a micro-costing approach to provide a precise and transparent analysis of the direct costs of cystoscopic procedures in Korean hospitals. The study seeks to identify key cost components and evaluate whether current reimbursement rates accurately reflect these direct costs.

Materials and methods: Significant variations in cost items were identified across different studies. An economic evaluation was conducted using a micro-costing methodology for the cost analysis of cystoscopic procedures, developed through literature review, data collection from studies, and expert consultations.

Results: Gangnam Severance Hospital (GSH) performed 2,188 cystoscopic procedures, including 1,847 cystoscopies and 341 JJ stent removals, with average costs of $100.8 and $110.6, respectively. At National Health Insurance Service Ilsan Hospital (NHIMC), 1,463 procedures were performed, including 1,167 cystoscopies and 296 JJ stent removals, with average costs of $119.2 and $125.3. Cystoscopy costs at GSH were driven by reprocessing ($45.8, 45.4%) and equipment ($33.1, 32.9%), while NHIMC's were $52.5 (44.0%) for equipment and $48.7 (40.8%) for reprocessing. Both hospitals incurred financial losses, with NHIS (National Health Insurance Service) covering only about 71.7% and 60.6% of costs for cystoscopy, and 71.0% and 62.7% for JJ stent removal.

Conclusions: The significant discrepancy between HIRA (Health Insurance Review & Assessment Service)'s estimated costs and those identified here suggests that current fees for cystoscopic procedures may be underestimated and require reassessment. Given the results, reevaluating these rates is essential to ensure fair compensation for healthcare providers and to deliver optimal patient care.

目的:本研究旨在利用微观成本法开发和实施经济评估,以提供韩国医院膀胱镜手术直接成本的精确和透明分析。这项研究旨在确定关键的成本组成部分,并评估目前的偿还率是否准确反映了这些直接成本。材料和方法:在不同的研究中发现了成本项目的显著差异。通过文献回顾、研究数据收集和专家咨询,采用微观成本法对膀胱镜手术的成本分析进行了经济评估。结果:江南Severance医院(GSH)实施了2188例膀胱镜手术,包括1847例膀胱镜检查和341例JJ支架移除手术,平均费用分别为100.8美元和110.6美元。在国民健康保险服务一山医院(NHIMC),进行了1,463例手术,包括1,167例膀胱镜检查和296例JJ支架移除,平均费用分别为119.2美元和125.3美元。GSH的膀胱镜检查费用由再处理(45.8美元,45.4%)和设备(33.1美元,32.9%)驱动,而NHIMC的设备费用为52.5美元(44.0%),再处理费用为48.7美元(40.8%)。两家医院都发生了经济损失,国民健康保险服务仅承担膀胱镜检查费用的71.7%和60.6%,JJ支架移除费用的71.0%和62.7%。结论:HIRA(健康保险审查与评估服务)估计的费用与本文确定的费用之间存在显著差异,表明目前膀胱镜检查的费用可能被低估,需要重新评估。鉴于这些结果,重新评估这些费率对于确保医疗保健提供者获得公平的补偿并提供最佳的患者护理至关重要。
{"title":"A multicenter micro-costing analysis of flexible cystoscopic procedures in Korea.","authors":"Uiemo Je, Woong Kyu Han, Hee-Kyo Jeong, Hankil Lee, Kwang Suk Lee, Sung Ku Kang, Byeong-Ju Kwon, Sung-Uk Kuh","doi":"10.4111/icu.20240289","DOIUrl":"10.4111/icu.20240289","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to develop and implement an economic evaluation using a micro-costing approach to provide a precise and transparent analysis of the direct costs of cystoscopic procedures in Korean hospitals. The study seeks to identify key cost components and evaluate whether current reimbursement rates accurately reflect these direct costs.</p><p><strong>Materials and methods: </strong>Significant variations in cost items were identified across different studies. An economic evaluation was conducted using a micro-costing methodology for the cost analysis of cystoscopic procedures, developed through literature review, data collection from studies, and expert consultations.</p><p><strong>Results: </strong>Gangnam Severance Hospital (GSH) performed 2,188 cystoscopic procedures, including 1,847 cystoscopies and 341 JJ stent removals, with average costs of $100.8 and $110.6, respectively. At National Health Insurance Service Ilsan Hospital (NHIMC), 1,463 procedures were performed, including 1,167 cystoscopies and 296 JJ stent removals, with average costs of $119.2 and $125.3. Cystoscopy costs at GSH were driven by reprocessing ($45.8, 45.4%) and equipment ($33.1, 32.9%), while NHIMC's were $52.5 (44.0%) for equipment and $48.7 (40.8%) for reprocessing. Both hospitals incurred financial losses, with NHIS (National Health Insurance Service) covering only about 71.7% and 60.6% of costs for cystoscopy, and 71.0% and 62.7% for JJ stent removal.</p><p><strong>Conclusions: </strong>The significant discrepancy between HIRA (Health Insurance Review & Assessment Service)'s estimated costs and those identified here suggests that current fees for cystoscopic procedures may be underestimated and require reassessment. Given the results, reevaluating these rates is essential to ensure fair compensation for healthcare providers and to deliver optimal patient care.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"87-96"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence can help individualize Wilms tumor treatment by predicting tumor response to preoperative chemotherapy. 人工智能可以通过预测肿瘤对术前化疗的反应来帮助个体化治疗肾母细胞瘤。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240135
Ahmed Nashat, Ahmed Alksas, Rasha T Aboulelkheir, Ahmed Elmahdy, Sherry M Khater, Hossam M Balaha, Israa Sharaby, Mohamed Shehata, Mohammed Ghazal, Salama Abd El-Wadoud, Ayman El-Baz, Ahmed Mosbah, Ahmed Abdelhalim

Purpose: To create a computer-aided prediction (CAP) system to predict Wilms tumor (WT) responsiveness to preoperative chemotherapy (PC) using pre-therapy contrast-enhanced computed tomography (CECT).

Materials and methods: A single-center database was reviewed for children <18 years diagnosed with WT and received PC between 2001 and 2021. Patients were excluded if pre- and post-PC CECT were not retrievable. According to the Response Evaluation Criteria in Solid Tumors criteria, volumetric response was considered favorable if PC resulted in ≥30% tumor volume reduction. Histological response was considered favorable if post-nephrectomy specimens had ≥66% necrosis. Four steps were used to create the prediction model: tumor delineation; extraction of shape, texture and functionality-based features; integration of the extracted features and selection of the prediction model with the highest diagnostic performance. K-fold cross-validation allowed the presentation of all data in the training and testing phases.

Results: A total of 63 tumors in 54 patients were used to train and test the prediction model. Patients were treated with 4-8 weeks of vincristine/actinomycin-D combination. Favorable volumetric and histologic responses were achieved in 46 tumors (73.0%) and 38 tumors (60.3%), respectively. Among machine learning classifiers, support vector machine had the best diagnostic performance with an accuracy, sensitivity, and specificity of 95.24%, 95.65%, and 94.12% for volumetric and 84.13%, 89.47%, 88% for histologic response prediction.

Conclusions: Based on pre-therapy CECT, CAP systems can help identify WT that are less likely to respond to PC with excellent accuracy. These tumors can be offered upfront surgery, avoiding the cons of PC.

目的:建立一个计算机辅助预测(CAP)系统,利用术前对比增强计算机断层扫描(CECT)预测Wilms肿瘤(WT)对术前化疗(PC)的反应性。材料和方法:对儿童单中心数据库进行回顾。结果:共使用54例患者的63个肿瘤对预测模型进行训练和测试。患者接受4-8周的长春新碱/放线菌素- d联合治疗。在46例肿瘤(73.0%)和38例肿瘤(60.3%)中分别获得了良好的体积和组织学反应。在机器学习分类器中,支持向量机对体积预测的准确率、灵敏度和特异性分别为95.24%、95.65%和94.12%,对组织反应预测的准确率、灵敏度和特异性分别为84.13%、89.47%和88%,具有最佳的诊断性能。结论:基于治疗前CECT, CAP系统可以帮助识别不太可能对PC有反应的WT,准确度很高。这些肿瘤可以进行前期手术,避免了PC的缺点。
{"title":"Artificial intelligence can help individualize Wilms tumor treatment by predicting tumor response to preoperative chemotherapy.","authors":"Ahmed Nashat, Ahmed Alksas, Rasha T Aboulelkheir, Ahmed Elmahdy, Sherry M Khater, Hossam M Balaha, Israa Sharaby, Mohamed Shehata, Mohammed Ghazal, Salama Abd El-Wadoud, Ayman El-Baz, Ahmed Mosbah, Ahmed Abdelhalim","doi":"10.4111/icu.20240135","DOIUrl":"10.4111/icu.20240135","url":null,"abstract":"<p><strong>Purpose: </strong>To create a computer-aided prediction (CAP) system to predict Wilms tumor (WT) responsiveness to preoperative chemotherapy (PC) using pre-therapy contrast-enhanced computed tomography (CECT).</p><p><strong>Materials and methods: </strong>A single-center database was reviewed for children <18 years diagnosed with WT and received PC between 2001 and 2021. Patients were excluded if pre- and post-PC CECT were not retrievable. According to the Response Evaluation Criteria in Solid Tumors criteria, volumetric response was considered favorable if PC resulted in ≥30% tumor volume reduction. Histological response was considered favorable if post-nephrectomy specimens had ≥66% necrosis. Four steps were used to create the prediction model: tumor delineation; extraction of shape, texture and functionality-based features; integration of the extracted features and selection of the prediction model with the highest diagnostic performance. K-fold cross-validation allowed the presentation of all data in the training and testing phases.</p><p><strong>Results: </strong>A total of 63 tumors in 54 patients were used to train and test the prediction model. Patients were treated with 4-8 weeks of vincristine/actinomycin-D combination. Favorable volumetric and histologic responses were achieved in 46 tumors (73.0%) and 38 tumors (60.3%), respectively. Among machine learning classifiers, support vector machine had the best diagnostic performance with an accuracy, sensitivity, and specificity of 95.24%, 95.65%, and 94.12% for volumetric and 84.13%, 89.47%, 88% for histologic response prediction.</p><p><strong>Conclusions: </strong>Based on pre-therapy CECT, CAP systems can help identify WT that are less likely to respond to PC with excellent accuracy. These tumors can be offered upfront surgery, avoiding the cons of PC.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"47-55"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and mortality of upper tract urothelial carcinoma in Korea: A nationwide population-based study conducted from 2002 to 2020. 韩国上尿路上皮癌的发病率和死亡率:一项2002年至2020年进行的全国性人群研究。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240255
Seongmin Moon, Yun-Sok Ha, Mina Kim, Hoseob Kim, Won Tae Kim, Yong-June Kim, Seok-Joong Yun, Sang-Cheol Lee, Ho Won Kang

Purpose: To describe the incidence and mortality of upper tract urothelial carcinoma (UTUC) from 2002-2020 using data from the Korean National Health Insurance Service, which contains data from the entire Korean population.

Materials and methods: Reimbursement records for 43,255 patients diagnosed with primary UTUC (according to the International Classification of Disease 10th revision code C65 and C66) between 2002-2020 were retrieved. The study period was split into four: period I (2002-2005), period II (2006-2010), period III (2011-2015), and period IV (2016-2020). Trends were quantified by calculating the annual percentage change (APC). Mortality data were obtained from the Statistics Korea.

Results: From 2002-2020, the incidence of UTUC in Korea increased gradually from 9.34 to 11.40 per 100,000 person-years. Although there was a male predominance, the male to female ratio did not change significantly over time; however, age at the time of diagnosis, the comorbidity index, and the proportion of patients undergoing open/laparoscopic surgery increased significantly over time. There was a modest improvement in 5-year survival (both all cause- and cancer-specific) over the study period. Multivariate analysis identified age at diagnosis, sex, the comorbidity index, and open/laparoscopic surgery as being associated with survival.

Conclusions: Between 2002 and 2020, the incidence of UTUC in Korea showed a general upward trend; however, survival outcomes have improved. These representative datasets from the Korean population might provide crucial information that enables clinicians to better understand of the epidemiology of UTUC in Korea.

目的:利用韩国国民健康保险服务的数据,描述2002-2020年期间上尿路上皮癌(UTUC)的发病率和死亡率,该数据包含了整个韩国人口的数据。材料和方法:检索2002-2020年间诊断为原发性UTUC的43255例患者的报销记录(根据国际疾病分类第10版修订代码C65和C66)。研究阶段分为四个阶段:第一阶段(2002-2005),第二阶段(2006-2010),第三阶段(2011-2015)和第四阶段(2016-2020)。通过计算年变化百分比(APC)来量化趋势。死亡率数据来自韩国统计局。结果:2002-2020年,韩国UTUC的发病率从9.34 / 10万人/年逐渐上升到11.40 / 10万人/年。虽然存在雄性优势,但男女比例随时间变化不显著;然而,随着时间的推移,诊断时的年龄、合并症指数和接受开放/腹腔镜手术的患者比例显著增加。在研究期间,5年生存率(包括所有原因和癌症特异性)略有改善。多变量分析确定诊断时的年龄、性别、合并症指数和开放/腹腔镜手术与生存率相关。结论:2002 ~ 2020年,韩国UTUC发病率总体呈上升趋势;然而,生存结果有所改善。这些来自韩国人群的代表性数据集可能提供关键信息,使临床医生能够更好地了解韩国UTUC的流行病学。
{"title":"Incidence and mortality of upper tract urothelial carcinoma in Korea: A nationwide population-based study conducted from 2002 to 2020.","authors":"Seongmin Moon, Yun-Sok Ha, Mina Kim, Hoseob Kim, Won Tae Kim, Yong-June Kim, Seok-Joong Yun, Sang-Cheol Lee, Ho Won Kang","doi":"10.4111/icu.20240255","DOIUrl":"10.4111/icu.20240255","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the incidence and mortality of upper tract urothelial carcinoma (UTUC) from 2002-2020 using data from the Korean National Health Insurance Service, which contains data from the entire Korean population.</p><p><strong>Materials and methods: </strong>Reimbursement records for 43,255 patients diagnosed with primary UTUC (according to the International Classification of Disease 10th revision code C65 and C66) between 2002-2020 were retrieved. The study period was split into four: period I (2002-2005), period II (2006-2010), period III (2011-2015), and period IV (2016-2020). Trends were quantified by calculating the annual percentage change (APC). Mortality data were obtained from the Statistics Korea.</p><p><strong>Results: </strong>From 2002-2020, the incidence of UTUC in Korea increased gradually from 9.34 to 11.40 per 100,000 person-years. Although there was a male predominance, the male to female ratio did not change significantly over time; however, age at the time of diagnosis, the comorbidity index, and the proportion of patients undergoing open/laparoscopic surgery increased significantly over time. There was a modest improvement in 5-year survival (both all cause- and cancer-specific) over the study period. Multivariate analysis identified age at diagnosis, sex, the comorbidity index, and open/laparoscopic surgery as being associated with survival.</p><p><strong>Conclusions: </strong>Between 2002 and 2020, the incidence of UTUC in Korea showed a general upward trend; however, survival outcomes have improved. These representative datasets from the Korean population might provide crucial information that enables clinicians to better understand of the epidemiology of UTUC in Korea.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"11-17"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rise in intraluminal temperature during ureteroscopy: Is this a concern? 输尿管镜检查时腔内温度升高:这是一个问题吗?
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240369
Hyung Joon Kim, Sung Kyu Hong

The global increase in urolithiasis prevalence has led to a shift towards minimally invasive procedures, such as retrograde intrarenal surgery, supported by advancements in laser technologies for lithotripsy. Pulsed lasers, particularly the holmium YAG and the newer thulium fiber laser, have significantly transformed the management of upper urinary tract stones. However, the use of high-power lasers in these procedures introduces risks of heat-related injury. Laser lithotripsy works through photothermal and photomechanical effects to fragment stones, but up to 96% of the laser energy is converted into heat, increasing the risk of thermal damage to the surrounding urothelial mucosa. Studies show that even at low-power settings, intrarenal temperatures can exceed the threshold for cellular injury, particularly in confined spaces like the ureter. This narrative review explores strategies to mitigate thermal injury, including optimizing laser settings, improving irrigation flow rates, and incorporating novel methods such as cold irrigation, controlling outflow resistance, and using suction. Understanding these approaches is crucial to enhancing patient safety during high-power laser lithotripsy procedures.

在激光碎石技术进步的支持下,全球尿石症患病率的增加导致了向微创手术(如逆行肾内手术)的转变。脉冲激光,特别是钬激光和较新的铥光纤激光,已经显著地改变了上尿路结石的治疗。然而,在这些过程中使用高功率激光会带来热相关伤害的风险。激光碎石术通过光热和光力学效应来粉碎结石,但高达96%的激光能量转化为热量,增加了对周围尿路上皮粘膜热损伤的风险。研究表明,即使在低功率环境下,静脉内温度也会超过细胞损伤的阈值,特别是在输尿管等狭窄空间。本文探讨了减轻热损伤的策略,包括优化激光设置、提高冲洗速率、结合冷冲洗、控制流出阻力和使用吸力等新方法。了解这些方法对于提高患者在高功率激光碎石过程中的安全性至关重要。
{"title":"Rise in intraluminal temperature during ureteroscopy: Is this a concern?","authors":"Hyung Joon Kim, Sung Kyu Hong","doi":"10.4111/icu.20240369","DOIUrl":"10.4111/icu.20240369","url":null,"abstract":"<p><p>The global increase in urolithiasis prevalence has led to a shift towards minimally invasive procedures, such as retrograde intrarenal surgery, supported by advancements in laser technologies for lithotripsy. Pulsed lasers, particularly the holmium YAG and the newer thulium fiber laser, have significantly transformed the management of upper urinary tract stones. However, the use of high-power lasers in these procedures introduces risks of heat-related injury. Laser lithotripsy works through photothermal and photomechanical effects to fragment stones, but up to 96% of the laser energy is converted into heat, increasing the risk of thermal damage to the surrounding urothelial mucosa. Studies show that even at low-power settings, intrarenal temperatures can exceed the threshold for cellular injury, particularly in confined spaces like the ureter. This narrative review explores strategies to mitigate thermal injury, including optimizing laser settings, improving irrigation flow rates, and incorporating novel methods such as cold irrigation, controlling outflow resistance, and using suction. Understanding these approaches is crucial to enhancing patient safety during high-power laser lithotripsy procedures.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robot-assisted ureteral reconstruction for managing kidney transplant patients with ureteric complications. 机器人辅助输尿管重建治疗肾移植患者输尿管并发症。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 DOI: 10.4111/icu.20240308
Dongho Shin, San Kang, Seung Ah Rhew, Chang Eil Yoon, Hyong Woo Moon, Yong Hyun Park, Hyuk Jin Cho

Purpose: To evaluate the feasibility of robot-assisted ureteral reconstruction as a minimally invasive alternative to open surgery for managing ureteric complications in transplanted kidneys.

Materials and methods: From January 2020 to December 2023, robot-assisted ureteral reconstruction was performed on fifteen kidney transplant patients with vesicoureteral reflux (VUR) or ureteral stricture who had previously failed endoscopic treatments.

Results: Twelve females and three males, with a mean age of 48.6±6.6 years, were included in the study. Nine patients (60.0%) underwent surgery due to VUR (grade III or higher) of the transplanted kidney, and six patients (40.0%) had transplanted ureteral strictures. Postoperative voiding cystourethrogram (VCUG) was performed at 3.2±1.6 months. Seven patients (77.8%) became VUR-free, while two patients (22.2%) had VUR regression from grade IV to I. All six patients who underwent reconstruction due to anastomosis site stricture became stenosis-free without the need for an indwelling ureteral catheter. In cases where the ureter was too short for reimplantation, a Boari flap or end-to-end anastomosis with the native ureter was performed. The mean hospital stay was 5.9±4.5 days. The urethral catheter was removed after 15.1±5.4 days, and the ureteral catheter was removed after 4.9±1.5 weeks. The mean follow-up period was 23.9±6.8 months, with no additional interventions required after surgery. No complications above Clavien-Dindo grade I were recorded.

Conclusions: Robotic ureteral reconstruction is technically feasible and offers an effective, minimally invasive treatment for ureteric complications in kidney transplant patients, serving as an alternative to open surgery.

目的:评估机器人辅助输尿管重建术作为一种微创替代开放手术治疗移植肾输尿管并发症的可行性。材料与方法:2020年1月至2023年12月,对15例既往内镜治疗失败的膀胱输尿管反流(VUR)或输尿管狭窄肾移植患者进行机器人辅助输尿管重建。结果:女性12例,男性3例,平均年龄48.6±6.6岁。9例(60.0%)患者因移植肾VUR (III级及以上)接受手术,6例(40.0%)患者因移植输尿管狭窄。术后3.2±1.6个月行膀胱输尿管造影(VCUG)。7例(77.8%)患者无VUR, 2例(22.2%)患者VUR从IV级降至i级。6例因吻合口狭窄进行重建的患者均无狭窄,无需留置输尿管导管。对于输尿管太短而不能再植入术的病例,采用Boari皮瓣或端到端与原输尿管吻合。平均住院时间5.9±4.5天。术后15.1±5.4天拔除导尿管,4.9±1.5周拔除输尿管导尿管。平均随访时间为23.9±6.8个月,术后无需额外干预。Clavien-Dindo I级以上无并发症记录。结论:机器人输尿管重建术在技术上是可行的,为肾移植患者输尿管并发症提供了一种有效的微创治疗方法,可作为开放手术的替代方案。
{"title":"Robot-assisted ureteral reconstruction for managing kidney transplant patients with ureteric complications.","authors":"Dongho Shin, San Kang, Seung Ah Rhew, Chang Eil Yoon, Hyong Woo Moon, Yong Hyun Park, Hyuk Jin Cho","doi":"10.4111/icu.20240308","DOIUrl":"10.4111/icu.20240308","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility of robot-assisted ureteral reconstruction as a minimally invasive alternative to open surgery for managing ureteric complications in transplanted kidneys.</p><p><strong>Materials and methods: </strong>From January 2020 to December 2023, robot-assisted ureteral reconstruction was performed on fifteen kidney transplant patients with vesicoureteral reflux (VUR) or ureteral stricture who had previously failed endoscopic treatments.</p><p><strong>Results: </strong>Twelve females and three males, with a mean age of 48.6±6.6 years, were included in the study. Nine patients (60.0%) underwent surgery due to VUR (grade III or higher) of the transplanted kidney, and six patients (40.0%) had transplanted ureteral strictures. Postoperative voiding cystourethrogram (VCUG) was performed at 3.2±1.6 months. Seven patients (77.8%) became VUR-free, while two patients (22.2%) had VUR regression from grade IV to I. All six patients who underwent reconstruction due to anastomosis site stricture became stenosis-free without the need for an indwelling ureteral catheter. In cases where the ureter was too short for reimplantation, a Boari flap or end-to-end anastomosis with the native ureter was performed. The mean hospital stay was 5.9±4.5 days. The urethral catheter was removed after 15.1±5.4 days, and the ureteral catheter was removed after 4.9±1.5 weeks. The mean follow-up period was 23.9±6.8 months, with no additional interventions required after surgery. No complications above Clavien-Dindo grade I were recorded.</p><p><strong>Conclusions: </strong>Robotic ureteral reconstruction is technically feasible and offers an effective, minimally invasive treatment for ureteric complications in kidney transplant patients, serving as an alternative to open surgery.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"18-26"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Investigative and Clinical Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1